{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:54:13Z","timestamp":1762642453847},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Oklahoma Shared Clinical and Translational Resources grant funded by NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human papillomavirus (HPV) is the leading cause of cervical cancer and has been implicated in several other cancer types including vaginal, vulvar, penile, and oropharyngeal cancers. Despite the recent availability of a vaccine, there are still over 310,000 deaths each year worldwide. Current treatments for HPV-mediated cancers show limited efficacy, and would benefit from improved understanding of disease mechanisms. Recently, we developed a <jats:italic>Drosophila<\/jats:italic> \u2018HPV 18 E6\u2019 model that displayed loss of cellular morphology and polarity, junctional disorganization, and degradation of the major E6 target Magi; we further provided evidence that mechanisms underlying HPV E6-induced cellular abnormalities are conserved between humans and flies. Here, we report a functional genetic screen of the <jats:italic>Drosophila<\/jats:italic> kinome that identified IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula>\u2014a regulator of NF-\u03baB\u2014as an enhancer of E6-induced cellular defects. We demonstrate that inhibition of IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> reduces Magi degradation and that this effect correlates with hyperphosphorylation of E6. Further, the reduction in IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> suppressed the cellular transformation caused by the cooperative action of HPVE6 and the oncogenic Ras. Finally, we demonstrate that the interaction between IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> and E6 is conserved in human cells: inhibition of IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> blocked the growth of cervical cancer cells, suggesting that IKK<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\beta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b2<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> may serve as a novel therapeutic target for HPV-mediated cancers.<\/jats:p>","DOI":"10.1038\/s41598-020-80193-5","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:15:21Z","timestamp":1610536521000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhibition of kinase IKK\u03b2 suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6"],"prefix":"10.1038","volume":"11","author":[{"given":"Mojgan","family":"Padash Barmchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashree V.","family":"Thatte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arushi","family":"Vats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross L.","family":"Cagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"80193_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 141, 664\u2013670. https:\/\/doi.org\/10.1002\/ijc.30716 (2017).","journal-title":"Int. J. Cancer"},{"key":"80193_CR2","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose, S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048\u20131056. https:\/\/doi.org\/10.1016\/S1470-2045(10)70230-8 (2010).","journal-title":"Lancet Oncol."},{"key":"80193_CR3","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn, M. et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health 8, e191\u2013e203. https:\/\/doi.org\/10.1016\/S2214-109X(19)30482-6 (2020).","journal-title":"Lancet Glob. Health"},{"key":"80193_CR4","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","volume":"16","author":"JT Schiller","year":"2015","unstructured":"Schiller, J. T. & Muller, M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 16, e217-225. https:\/\/doi.org\/10.1016\/S1470-2045(14)71179-9 (2015).","journal-title":"Lancet Oncol."},{"key":"80193_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1055-9965.EPI-12-1406","volume":"22","author":"M Schiffman","year":"2013","unstructured":"Schiffman, M. & Wentzensen, N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol. Biomark. Prev. 22, 553\u2013560. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1406 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"80193_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","volume":"12","author":"JG Skeate","year":"2016","unstructured":"Skeate, J. G., Woodham, A. W., Einstein, M. H., Da Silva, D. M. & Kast, W. M. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum. Vaccin Immunother. 12, 1418\u20131429. https:\/\/doi.org\/10.1080\/21645515.2015.1136039 (2016).","journal-title":"Hum. Vaccin Immunother."},{"key":"80193_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.soncn.2016.05.007","volume":"32","author":"TL Thomas","year":"2016","unstructured":"Thomas, T. L. Cancer prevention: HPV vaccination. Semin. Oncol. Nurs. 32, 273\u2013280. https:\/\/doi.org\/10.1016\/j.soncn.2016.05.007 (2016).","journal-title":"Semin. Oncol. Nurs."},{"key":"80193_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ajpath.2011.10.018","volume":"180","author":"WH Su","year":"2012","unstructured":"Su, W. H., Chuang, P. C., Huang, E. Y. & Yang, K. D. Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway. Am. J. Pathol. 180, 862\u2013871. https:\/\/doi.org\/10.1016\/j.ajpath.2011.10.018 (2012).","journal-title":"Am. J. Pathol."},{"key":"80193_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ctrv.2008.05.006","volume":"34","author":"D Pectasides","year":"2008","unstructured":"Pectasides, D., Kamposioras, K., Papaxoinis, G. & Pectasides, E. Chemotherapy for recurrent cervical cancer. Cancer Treat. Rev. 34, 603\u2013613. https:\/\/doi.org\/10.1016\/j.ctrv.2008.05.006 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"80193_CR10","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1128\/JVI.63.10.4417-4421.1989","volume":"63","author":"K Munger","year":"1989","unstructured":"Munger, K., Phelps, W. C., Bubb, V., Howley, P. M. & Schlegel, R. The E6-gene and E7-gene of the human papillomavirus type-16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417\u20134421 (1989).","journal-title":"J. Virol."},{"issue":"87","key":"80193_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/87.18.1365","volume":"I","author":"GYF Ho","year":"1995","unstructured":"Ho, G. Y. F. et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer I(87), 1365\u20131371. https:\/\/doi.org\/10.1093\/jnci\/87.18.1365 (1995).","journal-title":"J. Natl. Cancer"},{"key":"80193_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.2537532","volume":"243","author":"N Dyson","year":"1989","unstructured":"Dyson, N., Howley, P. M., Munger, K. & Harlow, E. The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene-product. Science 243, 934\u2013937. https:\/\/doi.org\/10.1126\/science.2537532 (1989).","journal-title":"Science"},{"key":"80193_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.2157286","volume":"248","author":"BA Werness","year":"1990","unstructured":"Werness, B. A., Levine, A. J. & Howley, P. M. Association of human papillomavirus type-16 and type-18 E6 proteins with P53. Science 248, 76\u201379. https:\/\/doi.org\/10.1126\/science.2157286 (1990).","journal-title":"Science"},{"key":"80193_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","volume":"63","author":"M Scheffner","year":"1990","unstructured":"Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129\u20131136 (1990).","journal-title":"Cell"},{"key":"80193_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1128\/JVI.02188-07","volume":"82","author":"WC Spanos","year":"2008","unstructured":"Spanos, W. C. et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 82, 2493\u20132500. https:\/\/doi.org\/10.1128\/JVI.02188-07 (2008).","journal-title":"J. Virol."},{"key":"80193_CR16","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1073\/pnas.94.21.11612","volume":"94","author":"T Kiyono","year":"1997","unstructured":"Kiyono, T. et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94, 11612\u201311616. https:\/\/doi.org\/10.1073\/pnas.94.21.11612 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"80193_CR17","doi-asserted-by":"publisher","first-page":"8244","DOI":"10.1128\/Mcb.20.21.8244-8253.2000","volume":"20","author":"S Nakagawa","year":"2000","unstructured":"Nakagawa, S. & Huibregtse, J. M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell Biol. 20, 8244\u20138253. https:\/\/doi.org\/10.1128\/Mcb.20.21.8244-8253.2000 (2000).","journal-title":"Mol. Cell Biol."},{"key":"80193_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.onc.1203374","volume":"19","author":"D Pim","year":"2000","unstructured":"Pim, D., Thomas, M., Javier, R., Gardiol, D. & Banks, L. HPV E6 targeted degradation of the discs large protein: Evidence for the involvement of a novel ubiquitin ligase. Oncogene 19, 719\u2013725. https:\/\/doi.org\/10.1038\/sj.onc.1203374 (2000).","journal-title":"Oncogene"},{"key":"80193_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1128\/JVI.01756-10","volume":"85","author":"C Kranjec","year":"2011","unstructured":"Kranjec, C. & Banks, L. A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions. J. Virol. 85, 1757\u20131764. https:\/\/doi.org\/10.1128\/JVI.01756-10 (2011).","journal-title":"J. Virol."},{"key":"80193_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/excr.2002.5475","volume":"275","author":"RP Laura","year":"2002","unstructured":"Laura, R. P., Ross, S., Koeppen, H. & Lasky, L. A. MAGI-1: A widely expressed, alternatively spliced tight junction protein. Exp. Cell Res. 275, 155\u2013170. https:\/\/doi.org\/10.1006\/excr.2002.5475 (2002).","journal-title":"Exp. Cell Res."},{"key":"80193_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrm.2016.80","volume":"17","author":"C Zihni","year":"2016","unstructured":"Zihni, C., Mills, C., Matter, K. & Balda, M. S. Tight junctions: From simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol. 17, 564\u2013580. https:\/\/doi.org\/10.1038\/nrm.2016.80 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"80193_CR22","doi-asserted-by":"publisher","first-page":"11544","DOI":"10.1128\/JVI.05410-11","volume":"85","author":"RT Javier","year":"2011","unstructured":"Javier, R. T. & Rice, A. P. Emerging theme: Cellular PDZ proteins as common targets of pathogenic viruses. J. Virol. 85, 11544\u201311556. https:\/\/doi.org\/10.1128\/JVI.05410-11 (2011).","journal-title":"J. Virol."},{"key":"80193_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","volume":"75","author":"M Scheffner","year":"1993","unstructured":"Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The Hpv-16 E6 and E6-Ap Complex Functions as a Ubiquitin-Protein Ligase in the Ubiquitination of P53. Cell 75, 495\u2013505. https:\/\/doi.org\/10.1016\/0092-8674(93)90384-3 (1993).","journal-title":"Cell"},{"key":"80193_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2091-9-S1-S4","author":"S Beaudenon","year":"2008","unstructured":"Beaudenon, S. & Huibregtse, J. M. HPV E6, E6AP and cervical cancer. BMC Biochem. https:\/\/doi.org\/10.1186\/1471-2091-9-S1-S4 (2008).","journal-title":"BMC Biochem."},{"key":"80193_CR25","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1128\/JVI.77.12.6957-6964.2003","volume":"77","author":"ML Nguyen","year":"2003","unstructured":"Nguyen, M. L., Nguyen, M. M., Lee, D., Griep, A. E. & Lambert, P. F. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6\u2019s induction of epithelial hyperplasia in vivo. J. Virol. 77, 6957\u20136964 (2003).","journal-title":"J. Virol."},{"key":"80193_CR26","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1038\/onc.2011.128","volume":"30","author":"G Halder","year":"2011","unstructured":"Halder, G. & Mills, G. B. Drosophila in cancer research: To boldly go where no one has gone before. Oncogene 30, 4063\u20134066. https:\/\/doi.org\/10.1038\/onc.2011.128 (2011).","journal-title":"Oncogene"},{"key":"80193_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mce.2008.02.009","volume":"293","author":"LI Gilbert","year":"2008","unstructured":"Gilbert, L. I. Drosophila is an inclusive model for human diseases, growth and development. Mol. Cell Endocrinol. 293, 25\u201331. https:\/\/doi.org\/10.1016\/j.mce.2008.02.009 (2008).","journal-title":"Mol. Cell Endocrinol."},{"key":"80193_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.gde.2005.12.004","volume":"16","author":"M Vidal","year":"2006","unstructured":"Vidal, M. & Cagan, R. L. Drosophila models for cancer research. Curr. Opin. Genet. Dev. 16, 10\u201316. https:\/\/doi.org\/10.1016\/j.gde.2005.12.004 (2006).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"80193_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1242\/dmm.007351","volume":"4","author":"M Crozatier","year":"2011","unstructured":"Crozatier, M. & Vincent, A. Drosophila: a model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias. Dis. Model Mech. 4, 439\u2013445. https:\/\/doi.org\/10.1242\/dmm.007351 (2011).","journal-title":"Dis. Model Mech."},{"key":"80193_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1039\/c9md00099b","volume":"10","author":"U Maitra","year":"2019","unstructured":"Maitra, U. & Ciesla, L. Using Drosophila as a platform for drug discovery from natural products in Parkinson\u2019s disease. Medchemcomm 10, 867\u2013879. https:\/\/doi.org\/10.1039\/c9md00099b (2019).","journal-title":"Medchemcomm"},{"key":"80193_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fgene.2019.00051","volume":"10","author":"Z Mirzoyan","year":"2019","unstructured":"Mirzoyan, Z. et al. Drosophila melanogaster: A model organism to study cancer. Front. Genet. 10, 51. https:\/\/doi.org\/10.3389\/fgene.2019.00051 (2019).","journal-title":"Front. Genet."},{"key":"80193_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbrc.2014.08.015","volume":"451","author":"S Ito","year":"2014","unstructured":"Ito, S. et al. A genetic screen in Drosophila for regulators of human prostate cancer progression. Biochem. Biophys. Res. Commun. 451, 548\u2013555. https:\/\/doi.org\/10.1016\/j.bbrc.2014.08.015 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"80193_CR33","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170156","author":"F Rossi","year":"2017","unstructured":"Rossi, F. et al. An in vivo genetic screen in Drosophila identifies the orthologue of human cancer\/testis gene SPO11 among a network of targets to inhibit lethal(3)malignant brain tumour growth. Open Biol. https:\/\/doi.org\/10.1098\/rsob.170156 (2017).","journal-title":"Open Biol."},{"key":"80193_CR34","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1534\/g3.117.044172","volume":"7","author":"AM Anderson","year":"2017","unstructured":"Anderson, A. M., Bailetti, A. A., Rodkin, E., De, A. & Bach, E. A. A genetic screen reveals an unexpected role for Yorkie signaling in JAK\/STAT-dependent hematopoietic malignancies in Drosophila melanogaster. G3 7, 2427\u20132438. https:\/\/doi.org\/10.1534\/g3.117.044172 (2017).","journal-title":"G3"},{"key":"80193_CR35","doi-asserted-by":"publisher","first-page":"e1005789","DOI":"10.1371\/journal.ppat.1005789","volume":"12","author":"M Padash Barmchi","year":"2016","unstructured":"Padash Barmchi, M. et al. A Drosophila model of HPV E6-induced malignancy reveals essential roles for magi and the insulin receptor. PLoS Pathog. 12, e1005789. https:\/\/doi.org\/10.1371\/journal.ppat.1005789 (2016).","journal-title":"PLoS Pathog."},{"key":"80193_CR36","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/hmg\/ddl225","volume":"15","author":"LT Reiter","year":"2006","unstructured":"Reiter, L. T., Seagroves, T. N., Bowers, M. & Bier, E. Expression of the Rho-GEF Pbl\/ECT2 is regulated by the UBE3A E3 ubiquitin ligase. Hum. Mol. Genet. 15, 2825\u20132835. https:\/\/doi.org\/10.1093\/hmg\/ddl225 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"80193_CR37","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1128\/JVI.01961-14","volume":"89","author":"SS Boon","year":"2015","unstructured":"Boon, S. S., Tomaic, V., Thomas, M., Roberts, S. & Banks, L. Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions. J. Virol. 89, 1579\u20131586. https:\/\/doi.org\/10.1128\/JVI.01961-14 (2015).","journal-title":"J. Virol."},{"key":"80193_CR38","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1167\/iovs.14-14671","volume":"55","author":"A Lennikov","year":"2014","unstructured":"Lennikov, A. et al. IkappaB kinase-beta inhibitor IMD-0354 beneficially suppresses retinal vascular permeability in streptozotocin-induced diabetic mice. Investig. Ophthalmol. Vis. Sci. 55, 6365\u20136373. https:\/\/doi.org\/10.1167\/iovs.14-14671 (2014).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"80193_CR39","doi-asserted-by":"publisher","first-page":"e0153259","DOI":"10.1371\/journal.pone.0153259","volume":"11","author":"M Padash Barmchi","year":"2016","unstructured":"Padash Barmchi, M., Samarasekera, G., Gilbert, M., Auld, V. J. & Zhang, B. Magi is associated with the par complex and functions antagonistically with bazooka to regulate the apical polarity complex. PLoS ONE 11, e0153259. https:\/\/doi.org\/10.1371\/journal.pone.0153259 (2016).","journal-title":"PLoS ONE"},{"key":"80193_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/dvdy.22738","volume":"241","author":"M Tsachaki","year":"2012","unstructured":"Tsachaki, M. & Sprecher, S. G. Genetic and developmental mechanisms underlying the formation of the Drosophila compound eye. Dev. Dyn. 241, 40\u201356. https:\/\/doi.org\/10.1002\/dvdy.22738 (2012).","journal-title":"Dev. Dyn."},{"key":"80193_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.16.1.225","volume":"16","author":"S Ghosh","year":"1998","unstructured":"Ghosh, S., May, M. J. & Kopp, E. B. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225\u2013260. https:\/\/doi.org\/10.1146\/annurev.immunol.16.1.225 (1998).","journal-title":"Annu. Rev. Immunol."},{"key":"80193_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/smim.2000.0210","volume":"12","author":"M Karin","year":"2000","unstructured":"Karin, M. & Delhase, M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin. Immunol. 12, 85\u201398. https:\/\/doi.org\/10.1006\/smim.2000.0210 (2000).","journal-title":"Semin. Immunol."},{"key":"80193_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu, S. & Karin, M. Regulation and function of NF-kappa B transcription factors in the immune system. Annu. Rev. Immunol. 27, 693\u2013733. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132641 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"80193_CR44","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","volume":"105","author":"A Tanaka","year":"2005","unstructured":"Tanaka, A. et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105, 2324\u20132331. https:\/\/doi.org\/10.1182\/blood-2004-08-3247 (2005).","journal-title":"Blood"},{"key":"80193_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0070-2153(09)89005-4","volume":"89","author":"R Cagan","year":"2009","unstructured":"Cagan, R. Principles of Drosophila eye differentiation. Curr. Top. Dev. Biol. 89, 115\u2013135. https:\/\/doi.org\/10.1016\/S0070-2153(09)89005-4 (2009).","journal-title":"Curr. Top. Dev. Biol."},{"key":"80193_CR46","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1038\/sj.onc.1203988","volume":"19","author":"C Kuhne","year":"2000","unstructured":"Kuhne, C., Gardiol, D., Guarnaccia, C., Amenitsch, H. & Banks, L. Differential regulation of human papillomavirus E6 by protein kinase A: Conditional degradation of human discs large protein by oncogenic E6. Oncogene 19, 5884\u20135891. https:\/\/doi.org\/10.1038\/sj.onc.1203988 (2000).","journal-title":"Oncogene"},{"key":"80193_CR47","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/Jvi.02074-12","volume":"87","author":"SS Boon","year":"2013","unstructured":"Boon, S. S. & Banks, L. High-risk human papillomavirus E6 oncoproteins interact with 14\u20133-3 zeta in a PDZ binding motif-dependent manner. J. Virol. 87, 1586\u20131595. https:\/\/doi.org\/10.1128\/Jvi.02074-12 (2013).","journal-title":"J. Virol."},{"key":"80193_CR48","first-page":"667","volume":"5","author":"DA Greenhalgh","year":"1994","unstructured":"Greenhalgh, D. A. et al. Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas. Cell Growth Differ. 5, 667\u2013675 (1994).","journal-title":"Cell Growth Differ."},{"key":"80193_CR49","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1038\/sj.onc.1207507","volume":"23","author":"K Schreiber","year":"2004","unstructured":"Schreiber, K. et al. Strong synergy between mutant ras and HPV16 E6\/E7 in the development of primary tumors. Oncogene 23, 3972\u20133979. https:\/\/doi.org\/10.1038\/sj.onc.1207507 (2004).","journal-title":"Oncogene"},{"key":"80193_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijc.2910530106","volume":"53","author":"K Anwar","year":"1993","unstructured":"Anwar, K., Nakakuki, K., Naiki, H. & Inuzuka, M. ras gene mutations and HPV infection are common in human laryngeal carcinoma. Int. J. Cancer 53, 22\u201328. https:\/\/doi.org\/10.1002\/ijc.2910530106 (1993).","journal-title":"Int. J. Cancer"},{"key":"80193_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gene.10150","volume":"34","author":"JB Duffy","year":"2002","unstructured":"Duffy, J. B. GAL4 system in Drosophila: A fly geneticist\u2019s Swiss army knife. Genesis 34, 1\u201315. https:\/\/doi.org\/10.1002\/gene.10150 (2002).","journal-title":"Genesis"},{"key":"80193_CR52","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001057","author":"LB Oliveira","year":"2018","unstructured":"Oliveira, L. B., Haga, I. R. & Villa, L. L. Human papillomavirus (HPV) 16 E6 oncoprotein targets the Toll-like receptor pathway. J. Gen. Virol. https:\/\/doi.org\/10.1099\/jgv.0.001057 (2018).","journal-title":"J. Gen. Virol."},{"key":"80193_CR53","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1128\/JVI.01942-05","volume":"80","author":"MA James","year":"2006","unstructured":"James, M. A., Lee, J. H. & Klingelhutz, A. J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 80, 5301\u20135307. https:\/\/doi.org\/10.1128\/JVI.01942-05 (2006).","journal-title":"J. Virol."},{"key":"80193_CR54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ijc.25400","volume":"128","author":"II Daud","year":"2011","unstructured":"Daud, I. I. et al. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int. J. Cancer 128, 879\u2013886. https:\/\/doi.org\/10.1002\/ijc.25400 (2011).","journal-title":"Int. J. Cancer"},{"key":"80193_CR55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1084\/jem.20122394","volume":"210","author":"UA Hasan","year":"2013","unstructured":"Hasan, U. A. et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 210, 1369\u20131387. https:\/\/doi.org\/10.1084\/jem.20122394 (2013).","journal-title":"J. Exp. Med."},{"key":"80193_CR56","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/carcin\/bgq176","volume":"31","author":"E Boccardo","year":"2010","unstructured":"Boccardo, E., Lepique, A. P. & Villa, L. L. The role of inflammation in HPV carcinogenesis. Carcinogenesis 31, 1905\u20131912. https:\/\/doi.org\/10.1093\/carcin\/bgq176 (2010).","journal-title":"Carcinogenesis"},{"key":"80193_CR57","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cyto.2010.11.014","volume":"53","author":"R Baker","year":"2011","unstructured":"Baker, R. et al. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine 53, 282\u2013285. https:\/\/doi.org\/10.1016\/j.cyto.2010.11.014 (2011).","journal-title":"Cytokine"},{"key":"80193_CR58","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1158\/1055-9965.EPI-10-0184","volume":"19","author":"TJ Kemp","year":"2010","unstructured":"Kemp, T. J. et al. Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol. Biomarkers Prev. 19, 1954\u20131959. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-0184 (2010).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"80193_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cyto.2016.04.002","volume":"83","author":"JO Lam","year":"2016","unstructured":"Lam, J. O. et al. Association of serum cytokines with oral HPV clearance. Cytokine 83, 85\u201391. https:\/\/doi.org\/10.1016\/j.cyto.2016.04.002 (2016).","journal-title":"Cytokine"},{"key":"80193_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fimmu.2014.00464","volume":"5","author":"AM Rich","year":"2014","unstructured":"Rich, A. M., Hussaini, H. M., Parachuru, V. P. & Seymour, G. J. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front. Immunol. 5, 464. https:\/\/doi.org\/10.3389\/fimmu.2014.00464 (2014).","journal-title":"Front. Immunol."},{"key":"80193_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2015.03.010","volume":"573","author":"XF Ma","year":"2015","unstructured":"Ma, X. F. et al. IKKbeta\/NF-kappaB mediated the low doses of bisphenol A induced migration of cervical cancer cells. Arch. Biochem. Biophys. 573, 52\u201358. https:\/\/doi.org\/10.1016\/j.abb.2015.03.010 (2015).","journal-title":"Arch. Biochem. Biophys."},{"key":"80193_CR62","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1101\/gad.909001","volume":"15","author":"N Silverman","year":"2001","unstructured":"Silverman, N. & Maniatis, T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15, 2321\u20132342. https:\/\/doi.org\/10.1101\/gad.909001 (2001).","journal-title":"Genes Dev."},{"key":"80193_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF02786486","volume":"19","author":"S Ghosh","year":"1999","unstructured":"Ghosh, S. Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol. Res. 19, 183\u2013189. https:\/\/doi.org\/10.1007\/BF02786486 (1999).","journal-title":"Immunol. Res."},{"key":"80193_CR64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/onc.2013.49","volume":"33","author":"LK Nottingham","year":"2014","unstructured":"Nottingham, L. K. et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR\/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 33, 1135\u20131147. https:\/\/doi.org\/10.1038\/onc.2013.49 (2014).","journal-title":"Oncogene"},{"key":"80193_CR65","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-09-3912","volume":"70","author":"L Hernandez","year":"2010","unstructured":"Hernandez, L. et al. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 70, 4005\u20134014. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3912 (2010).","journal-title":"Cancer Res."},{"key":"80193_CR66","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/ijc.24854","volume":"126","author":"R Jiang","year":"2010","unstructured":"Jiang, R. et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int. J. Cancer 126, 1263\u20131274. https:\/\/doi.org\/10.1002\/ijc.24854 (2010).","journal-title":"Int. J. Cancer"},{"key":"80193_CR67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.2157286","volume":"248","author":"BA Werness","year":"1990","unstructured":"Werness, B. A., Levine, A. J. & Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76\u201379 (1990).","journal-title":"Science"},{"key":"80193_CR68","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1073\/pnas.0812256106","volume":"106","author":"Y Xia","year":"2009","unstructured":"Xia, Y. et al. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA 106, 2629\u20132634. https:\/\/doi.org\/10.1073\/pnas.0812256106 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"80193_CR69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1582-4934.2009.00712.x","volume":"14","author":"PM Yang","year":"2010","unstructured":"Yang, P. M. et al. Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J. Cell Mol. Med. 14, 687\u2013698. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00712.x (2010).","journal-title":"J. Cell Mol. Med."},{"key":"80193_CR70","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1128\/MCB.00964-10","volume":"31","author":"R Accardi","year":"2011","unstructured":"Accardi, R. et al. IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol 31, 2210\u20132226. https:\/\/doi.org\/10.1128\/MCB.00964-10 (2011).","journal-title":"Mol Cell Biol"},{"key":"80193_CR71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0092-8674(04)00302-2","volume":"117","author":"MC Hu","year":"2004","unstructured":"Hu, M. C. et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225\u2013237 (2004).","journal-title":"Cell"},{"key":"80193_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.leu.2403998","volume":"20","author":"D Cilloni","year":"2006","unstructured":"Cilloni, D. et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 20, 61\u201367. https:\/\/doi.org\/10.1038\/sj.leu.2403998 (2006).","journal-title":"Leukemia"},{"key":"80193_CR73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.onc.1209066","volume":"25","author":"A Yemelyanov","year":"2006","unstructured":"Yemelyanov, A. et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25, 387\u2013398. https:\/\/doi.org\/10.1038\/sj.onc.1209066 (2006).","journal-title":"Oncogene"},{"key":"80193_CR74","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-05-1220","volume":"12","author":"J Yang","year":"2006","unstructured":"Yang, J., Amiri, K. I., Burke, J. R., Schmid, J. A. & Richmond, A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12, 950\u2013960. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1220 (2006).","journal-title":"Clin. Cancer Res."},{"key":"80193_CR75","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.oraloncology.2014.02.004","volume":"50","author":"J Johnson","year":"2014","unstructured":"Johnson, J., Shi, Z., Liu, Y. & Stack, M. S. Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma. Oral Oncol. 50, 468\u2013477. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.02.004 (2014).","journal-title":"Oral Oncol."},{"key":"80193_CR76","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3978\/j.issn.2218-676X.2012.05.04","volume":"1","author":"L Shao","year":"2012","unstructured":"Shao, L., Wu, L. & Zhou, D. Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor kappaB kinase. Transl. Cancer Res. 1, 100\u2013108. https:\/\/doi.org\/10.3978\/j.issn.2218-676X.2012.05.04 (2012).","journal-title":"Transl. Cancer Res."},{"key":"80193_CR77","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000161579","volume":"148","author":"A Sugita","year":"2009","unstructured":"Sugita, A. et al. Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. Int. Arch. Allergy Immunol. 148, 186\u2013198. https:\/\/doi.org\/10.1159\/000161579 (2009).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"80193_CR78","first-page":"49","volume":"55","author":"T Ochiai","year":"2008","unstructured":"Ochiai, T. et al. Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. J. Med. Dent. Sci. 55, 49\u201359 (2008).","journal-title":"J. Med. Dent. Sci."},{"key":"80193_CR79","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1349-7006.2011.02110.x","volume":"103","author":"S Uota","year":"2012","unstructured":"Uota, S. et al. An IkappaB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer Sci. 103, 100\u2013106. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02110.x (2012).","journal-title":"Cancer Sci."},{"key":"80193_CR80","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00535-009-0098-7","volume":"44","author":"Y Hayakawa","year":"2009","unstructured":"Hayakawa, Y. et al. Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis. J. Gastroenterol. 44, 935\u2013943. https:\/\/doi.org\/10.1007\/s00535-009-0098-7 (2009).","journal-title":"J. Gastroenterol."},{"key":"80193_CR81","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1038\/bcj.2011.9","volume":"1","author":"M Kanduri","year":"2011","unstructured":"Kanduri, M., Tobin, G., Aleskog, A., Nilsson, K. & Rosenquist, R. The novel NF-kappaB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia. Blood Cancer J. 1, e12. https:\/\/doi.org\/10.1038\/bcj.2011.9 (2011).","journal-title":"Blood Cancer J."},{"key":"80193_CR82","doi-asserted-by":"publisher","first-page":"10003","DOI":"10.1038\/s41598-019-46447-7","volume":"9","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. Sci. Rep. 9, 10003. https:\/\/doi.org\/10.1038\/s41598-019-46447-7 (2019).","journal-title":"Sci. Rep."},{"key":"80193_CR83","doi-asserted-by":"publisher","first-page":"36287","DOI":"10.1074\/jbc.M404568200","volume":"279","author":"TT Maliekal","year":"2004","unstructured":"Maliekal, T. T., Anto, R. J. & Karunagaran, D. Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-beta. J. Biol. Chem. 279, 36287\u201336292. https:\/\/doi.org\/10.1074\/jbc.M404568200 (2004).","journal-title":"J. Biol. Chem."},{"key":"80193_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s0304-3835(96)04362-5","volume":"108","author":"K Funaoka","year":"1996","unstructured":"Funaoka, K. et al. High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1\/Cip1 level. Cancer Lett. 108, 15\u201323. https:\/\/doi.org\/10.1016\/s0304-3835(96)04362-5 (1996).","journal-title":"Cancer Lett."},{"key":"80193_CR85","doi-asserted-by":"publisher","first-page":"574659","DOI":"10.1155\/2014\/574659","volume":"2014","author":"M Filippova","year":"2014","unstructured":"Filippova, M. et al. Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed. Res. Int. 2014, 574659. https:\/\/doi.org\/10.1155\/2014\/574659 (2014).","journal-title":"Biomed. Res. Int."},{"key":"80193_CR86","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7269","author":"KI Pappa","year":"2019","unstructured":"Pappa, K. I. et al. High resolution analysis of the intracellular proteome of cervical cancer cell lines unveils novel regulators of cervical carcinogenesis. Oncol. Rep. https:\/\/doi.org\/10.3892\/or.2019.7269 (2019).","journal-title":"Oncol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80193-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:57:20Z","timestamp":1670032640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80193-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80193"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80193-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1111"}}